Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

News tagged with 'Palivizumab'

Synagis Label Revised
Posted by Staff Writer
November 27, 2002 12:00 AM

FDA and MedImmune have revised the WARNINGS, OVERDOSAGE, and POST MARKETING EXPERIENCE sections of the Synagis (palivizumab) label to provide clarification on the risk of anaphylaxis (hypersensitivity) based on worldwide post-marketing experience. Very rare cases of anaphylaxis have been reported following re-exposure

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact InjuryBoard.com

Subscribe

RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes